We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

83 hedge funds and large institutions have $4.79M invested in VistaGen Therapeutics in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

1% more capital invested

Capital invested by funds: $4.75M → $4.79M (+$38.4K)

0.07% less ownership

Funds ownership: 0.66% → 0.58% (-0.07%)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

2% less funds holding

Funds holding: 85 → 83 (-2)

Holders
83
Holders Change
-2
Holders Change %
-2.35%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
24
Reduced
18
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$163K
2
State Street
State Street
Massachusetts
+$47.1K
3
Allspring Global Investments
Allspring Global Investments
North Carolina
+$37.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$36.4K
5
HNWA
Henrickson Nauta Wealth Advisors
Michigan
+$35K

Top Sellers

1
GCP
GSA Capital Partners
United Kingdom
-$668K
2
N
Nuveen
North Carolina
-$597K
3
Two Sigma Investments
Two Sigma Investments
New York
-$57.6K
4
Citadel Advisors
Citadel Advisors
Florida
-$37K
5
Morgan Stanley
Morgan Stanley
New York
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$1.65M +$163K +31,150 +8%
State Street
2
State Street
Massachusetts
$802K +$47.1K +8,975 +4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$616K +$36.4K +6,940 +4%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$430K +$31K +5,907 +5%
Northern Trust
5
Northern Trust
Illinois
$230K +$16.5K +3,138 +5%
GCP
6
GSA Capital Partners
United Kingdom
$159K -$668K -127,338 -75%
MCM
7
MAI Capital Management
Ohio
$72.9K -$5.73K -1,093 -5%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$72.2K – – –
Charles Schwab
9
Charles Schwab
California
$61.7K +$11.6K +2,219 +16%
Two Sigma Investments
10
Two Sigma Investments
New York
$41.3K -$57.6K -10,990 -50%
AllianceBernstein
11
AllianceBernstein
Tennessee
$39.4K – – –
RhumbLine Advisers
12
RhumbLine Advisers
Massachusetts
$32K +$2.81K +535 +7%
GWSG
13
GPS Wealth Strategies Group
Colorado
$31.6K – – –
Deutsche Bank
14
Deutsche Bank
Germany
$31.5K +$28.8K +5,484 +188%
Allspring Global Investments
15
Allspring Global Investments
North Carolina
$26.5K +$37.1K +7,081 New
HNWA
16
Henrickson Nauta Wealth Advisors
Michigan
$24.9K +$35K +6,667 New
UBS Group
17
UBS Group
Switzerland
$24.7K +$2.56K +488 +8%
JJ
18
Johnson & Johnson
New Jersey
$23.8K +$33.3K +6,350 New
Morgan Stanley
19
Morgan Stanley
New York
$22.8K -$11.6K -2,208 -27%
Principal Financial Group
20
Principal Financial Group
Iowa
$22.5K -$1.76K -335 -5%
JP Morgan Chase
21
JP Morgan Chase
New York
$20K +$8.44K +1,610 +44%
Wells Fargo
22
Wells Fargo
California
$17.7K +$6.83K +1,302 +38%
TA
23
TKG Advisors
Indiana
$16.8K – – –
New York State Common Retirement Fund
24
New York State Common Retirement Fund
New York
$16.7K – – –
HighTower Advisors
25
HighTower Advisors
Illinois
$15K – – –
1
2 3 4

VTGN Hedge Fund Activity: Q1 2023 in Review

83 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2023, worth a combined $4.79M — up 0.81% from $4.75M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of VTGN and 12 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 24 added.

The largest buyer was BlackRock, adding an estimated $163K. The largest seller was GSA Capital Partners, cutting an estimated $668K.

  • 83 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $4.79M of VistaGen Therapeutics stock for Q1 2023, up 0.81% quarter-over-quarter.
  • 12 funds opened new VistaGen Therapeutics positions in Q1 2023 and 13 closed out, a net change of -1 holder.
  • The largest VistaGen Therapeutics buyer in Q1 2023 was BlackRock, an estimated $163K added.
  • The largest VistaGen Therapeutics seller in Q1 2023 was GSA Capital Partners, an estimated $668K sold.

Based on aggregated 13F filings for Q1 2023.